Key Insights

The French continuous glucose monitoring (CGM) market, valued at €1.3 billion in 2025, is poised for substantial growth, projected to expand at a compound annual growth rate (CAGR) of 6.58% from 2025 to 2033. This growth is fueled by several key factors. Increasing prevalence of diabetes, particularly type 1 and type 2, coupled with rising awareness of the benefits of CGM technology among both patients and healthcare professionals, are primary drivers. CGM systems offer superior glycemic control compared to traditional self-monitoring blood glucose (SMBG) methods, leading to improved patient outcomes and reduced long-term complications. Furthermore, technological advancements, such as the development of smaller, more user-friendly devices with enhanced accuracy and integration with smart devices, are contributing to market expansion. The market is segmented into various components, including monitoring devices (CGM and SMBG), lancets, and management devices like insulin pumps and infusion sets. Major players such as Roche, Abbott, Dexcom, Medtronic, and Insulet are actively competing in this market, driving innovation and competition. Government initiatives promoting diabetes management and reimbursement policies for CGM technology further bolster market growth.

Despite this positive outlook, challenges remain. The relatively high cost of CGM systems compared to SMBG, coupled with insurance coverage limitations, can hinder market penetration. Furthermore, potential issues with device accuracy, sensor calibration requirements, and the need for skilled personnel for device management could create barriers to adoption. However, ongoing research and development efforts aimed at addressing these issues, along with increasing patient demand, suggest that the CGM market in France will continue its trajectory of robust growth throughout the forecast period. Companies are focusing on developing integrated solutions that combine CGM data with insulin delivery systems, providing a more holistic approach to diabetes management. This trend is expected to further drive the growth of the market in the coming years.

This comprehensive report provides an in-depth analysis of the Continuous Glucose Monitor (CGM) industry in France, covering the period from 2019 to 2033. It offers valuable insights for industry stakeholders, including manufacturers, investors, and healthcare professionals, by examining market dynamics, competitive landscapes, and future growth prospects. The report utilizes data from 2019-2024 (Historical Period), with 2025 as the Base and Estimated Year, and projects market trends up to 2033 (Forecast Period).

Continuous Glucose Monitor Industry in France Market Concentration & Innovation

The French CGM market exhibits a moderately concentrated structure, with key players like Roche, Insulet, Lifescan (Johnson & Johnson), Dexcom, Becton Dickinson, Ypsomed, Abbott, Novo Nordisk, Eli Lilly, Sanofi, Medtronic, and Tandem holding significant market share. However, the market is also witnessing increased competition from emerging players and innovative technologies. Market share analysis reveals that the top 7 companies control approximately xx% of the market (2025 estimate), with Roche and Abbott potentially holding the largest individual shares. M&A activity has been moderate, with recent deals primarily focusing on strategic partnerships to integrate CGM systems with insulin delivery devices. Deal values for these partnerships have ranged from xx Million to xx Million euros, reflecting the strategic importance of integrated solutions. Innovation is driven by advancements in sensor technology, data analytics, and connectivity, leading to smaller, more accurate, and user-friendly devices. The regulatory framework in France is crucial, influencing market access and reimbursement policies for CGM devices. End-user trends indicate a growing preference for continuous monitoring over self-monitoring blood glucose (SMBG) due to improved convenience and enhanced diabetes management capabilities. The substitution of SMBG devices by CGM devices presents a significant growth opportunity.

Continuous Glucose Monitor Industry in France Industry Trends & Insights

The French CGM market is experiencing robust growth, driven by increasing diabetes prevalence, rising awareness of the benefits of continuous glucose monitoring, technological advancements resulting in improved device accuracy and usability, and supportive government initiatives aimed at improving diabetes care. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of xx% during the forecast period (2025-2033), reaching a market size of xx Million euros by 2033. This growth is propelled by increasing adoption rates among both type 1 and type 2 diabetes patients. Market penetration is expected to increase significantly due to improving accessibility and affordability of CGMs. Technological disruptions such as the integration of CGM with insulin pumps and smartphone applications are streamlining diabetes management, further accelerating market growth. Consumer preferences are shifting towards real-time data insights, seamless integration with other devices, and improved accuracy to support personalized diabetes management. The competitive landscape remains dynamic, with existing players investing heavily in R&D and new market entrants emerging.

Dominant Markets & Segments in Continuous Glucose Monitor Industry in France

• Leading Region/Segment: The Île-de-France region is projected to be the dominant market segment, driven by high diabetes prevalence, better healthcare infrastructure and higher concentration of specialized diabetes centers.

• Monitoring Devices:

  • Self-monitoring Blood Glucose Devices (SMBG): While facing competition from CGMs, SMBG devices still hold a significant market share due to lower cost. However, this segment is expected to see slower growth compared to CGM.
  • Continuous Blood Glucose Monitoring (CGM): This segment is the fastest-growing, driven by the aforementioned technological advancements and increased awareness among patients and healthcare providers.

• Management Devices:

  • Insulin Pumps: The insulin pump segment shows strong growth, driven by the increasing preference for automated insulin delivery systems which often integrate with CGM technology.
  • Infusion Sets, Insulin Syringes, Insulin Cartridges, Disposable Pens: These consumable segments are directly tied to the growth of CGM and insulin pump markets, representing a substantial revenue stream.

Dominance Analysis: The shift towards CGM is driving the dominance of this segment within the overall market. The increasing affordability and acceptance of integrated CGM systems, combined with supportive government policies, are fueling this growth. The increasing demand for advanced diabetes management solutions is creating a favorable environment for sophisticated CGM systems.

Continuous Glucose Monitor Industry in France Product Developments

Recent product innovations include smaller, more accurate sensors, improved data analytics capabilities, and seamless integration with smartphone apps and insulin pumps. These advancements enhance usability, improve the accuracy of glucose readings, and provide more personalized diabetes management. The integration of AI algorithms for predictive analytics is further improving the clinical utility of CGMs, making them indispensable tools for managing diabetes effectively. The market fit for these advanced CGMs is high, given the growing demand for more convenient and accurate solutions.

Report Scope & Segmentation Analysis

This report segments the French CGM market by device type (Self-Monitoring Blood Glucose Devices, Continuous Glucose Monitoring Devices), management devices (Insulin Pumps, Infusion Sets, Insulin Syringes, Insulin Cartridges, Disposable Pens), and geographical region. Growth projections are provided for each segment, offering detailed market size estimations, and assessing competitive dynamics for each market segment. The market exhibits high growth potential in the CGM segment due to growing diabetes prevalence and technological advancements leading to higher accuracy, smaller sizes, and improved ease of use, causing a gradual decline in demand for SMBG devices.

Key Drivers of Continuous Glucose Monitor Industry in France Growth

Several factors drive the growth of the CGM industry in France, including:

• Rising prevalence of diabetes: The increasing number of individuals with diabetes necessitates advanced monitoring solutions.
• Technological advancements: Improved accuracy, smaller sensor sizes, and wireless connectivity enhance usability.
• Favorable reimbursement policies: Government initiatives facilitating access to CGM technology drive adoption.
• Growing awareness: Increased patient and physician awareness of the benefits of CGM improves acceptance.

Challenges in the Continuous Glucose Monitor Industry in France Sector

Significant challenges include:

• High cost of devices and consumables: This limits accessibility for some patients.
• Regulatory hurdles: Stringent regulatory requirements can delay market entry for new products.
• Competition: Intense competition among established and emerging players puts pressure on pricing and profitability.
• Supply chain disruptions: Global supply chain challenges affect device availability. These factors collectively affect market penetration and growth rates.

Emerging Opportunities in Continuous Glucose Monitor Industry in France

• Integration with other devices: Expanding integration with insulin pumps and other digital health tools creates new opportunities.
• Data analytics and AI: Leveraging data for personalized diabetes management offers significant growth potential.
• Telemedicine and remote monitoring: Remote patient monitoring utilizing CGM data enhances care access.
• New market segments: Targeting specific patient populations (e.g., pregnant women with diabetes) expands market reach.

Leading Players in the Continuous Glucose Monitor Industry in France Market

• Roche
• Insulet
• Lifescan (Johnson & Johnson)
• Dexcom
• Becton Dickinson
• Ypsomed
• Abbott
• Novo Nordisk
• Eli Lilly
• Sanofi
• Medtronic
• Tandem

Key Developments in Continuous Glucose Monitor Industry in France Industry

• September 2023: Dexcom launches Dexcom ONE CGM system in France, expanding access for an additional half a million individuals.
• April 2022: CamDiab and Ypsomed partner to develop an integrated automated insulin delivery (AID) system, connecting Abbott's FreeStyle Libre 3 sensor with CamDiab's app and Ypsomed's pump.

Strategic Outlook for Continuous Glucose Monitor Industry in France Market

The French CGM market holds substantial future potential driven by technological advancements, rising diabetes prevalence, increased awareness, and supportive regulatory frameworks. Opportunities exist in integrating CGM with other digital health solutions, expanding data analytics capabilities, and developing new products tailored to specific patient needs. The market is poised for continued growth, creating lucrative opportunities for both established and emerging players.

Continuous Glucose Monitor Industry in France Segmentation

• 1. Monitoring Devices
  • 1.1. Self-monitoring Blood Glucose Devices
    • 1.1.1. Glucometer Devices
    • 1.1.2. Test Strips
    • 1.1.3. Lancets
  • 1.2. Continuous Blood Glucose Monitoring
    • 1.2.1. Sensors
    • 1.2.2. Durables
• 2. Management Devices
  • 2.1. Insulin Pump
    • 2.1.1. Insulin Pump Device
    • 2.1.2. Insulin Pump Reservoir
    • 2.1.3. Infusion Set
  • 2.2. Insulin Syringes
  • 2.3. Insulin Cartridges
  • 2.4. Disposable Pens

Continuous Glucose Monitor Industry in France Segmentation By Geography

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific